DRRX DURECT Corporation

2.11
-0.4  -16%
Previous Close 2.51
Open 2.39
Price To Book 19.18
Market Cap 405,884,198
Shares 192,362,179
Volume 2,760,473
Short Ratio
Av. Daily Volume 1,509,499
Stock charts supplied by TradingView

NewsSee all news

  1. DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR®

    CUPERTINO, Calif., Jan. 17, 2020 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)

  2. DURECT Corporation Trading Halted Today; FDA Advisory Committee to Discuss POSIMIR® (bupivacaine extended-release solution) for Post-Surgical Analgesia

    CUPERTINO, Calif., Jan. 16, 2020 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that NASDAQ has halted trading of the Company's common stock today. The U.S. Food and Drug Administration's (FDA)

  3. DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis

    CUPERTINO, Calif., Jan. 2, 2020 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two

  4. DURECT to Present at the Stifel 2019 Health Care Conference

    CUPERTINO, Calif., Nov. 15, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Stifel 2019 Health Care Conference, at the Lotte New

  5. DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting®

    CUPERTINO, Calif., Nov. 12, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in alcoholic hepatitis (AH), presented as a late-breaking oral

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced July 27, 2018.
RBP-7000
Schizophrenia
Phase 2 top-line data did not meet endpoints - January 2, 2020.
DUR-928
Psoriasis
CRL issued February 12, 2014.
Posidur
Post-operative pain relief
CRL Feb 12 2014. Advisory Committee meeting voted 6-6 January 16, 2020 regarding approval. PDUFA date of December 27, 2019 was not met due to the meeting. No guidance announced regarding new timeline.
POSIMIR
Post-operative pain relief
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Phase 2 trial to be completed 1H 2020 with data due following completion of trial.
DUR-928
Nonalcoholic steatohepatitis (NASH)
Phase 2b trial to commence mid-2020 with data due 2022.
DUR-928
Alcoholic hepatitis (AH)

Latest News

  1. DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR®

    CUPERTINO, Calif., Jan. 17, 2020 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)

  2. DURECT Corporation Trading Halted Today; FDA Advisory Committee to Discuss POSIMIR® (bupivacaine extended-release solution) for Post-Surgical Analgesia

    CUPERTINO, Calif., Jan. 16, 2020 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that NASDAQ has halted trading of the Company's common stock today. The U.S. Food and Drug Administration's (FDA)

  3. DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis

    CUPERTINO, Calif., Jan. 2, 2020 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two

  4. DURECT to Present at the Stifel 2019 Health Care Conference

    CUPERTINO, Calif., Nov. 15, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Stifel 2019 Health Care Conference, at the Lotte New

  5. DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting®

    CUPERTINO, Calif., Nov. 12, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in alcoholic hepatitis (AH), presented as a late-breaking oral

  6. DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results

    CUPERTINO, Calif., Nov. 6, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that it will host a key opinion leader (KOL) conference call and live webcast to discuss the results of its recently

  7. DURECT Corporation Announces Third Quarter 2019 Financial Results and Update of Programs

    CUPERTINO, Calif., Nov. 4, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2019 and provided a corporate update. Total revenues were $10.8

  8. DURECT Corporation to Announce Third Quarter 2019 Financial Results and Provide Business Update on November 4

    CUPERTINO, Calif., Oct. 30, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it will report third quarter and nine months ended September 30, 2019 financial results and host a conference call

  9. DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH

    CUPERTINO, Calif., Oct. 7, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in patients with mild to moderate plaque

  10. DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain

    CUPERTINO, Calif., Oct. 2, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its Class 2 NDA resubmission for POSIMIR®

  11. DURECT to Present at the 2019 Cantor Fitzgerald Global Health Care Conference

    CUPERTINO, Calif., Sept. 26, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the Cantor Fitzgerald Global Health Care Conference,

  12. DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis

    CUPERTINO, Calif., Sept. 17, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic

  13. DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology

    CUPERTINO, Calif., Sept. 9, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that further development of a long-acting injectable HIV investigational product utilizing DURECT's SABER® technology

  14. DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright

    CUPERTINO, Calif., Sept. 4, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment